iBio (IBIO) Liabilities from Discontinued Operations (2022 - 2024)
Historic Liabilities from Discontinued Operations for iBio (IBIO) over the last 4 years, with Q1 2024 value amounting to $1.9 million.
- iBio's Liabilities from Discontinued Operations fell 56.58% to $1.9 million in Q1 2024 from the same period last year, while for Mar 2024 it was $1.9 million, marking a year-over-year decrease of 56.58%. This contributed to the annual value of $1.9 million for FY2023, which is 152.21% down from last year.
- iBio's Liabilities from Discontinued Operations amounted to $1.9 million in Q1 2024, which was down 56.58% from $1.9 million recorded in Q4 2023.
- iBio's Liabilities from Discontinued Operations' 5-year high stood at $2.0 million during Q2 2022, with a 5-year trough of $1.9 million in Q1 2024.
- In the last 3 years, iBio's Liabilities from Discontinued Operations had a median value of $1.9 million in 2023 and averaged $1.9 million.
- Data for iBio's Liabilities from Discontinued Operations shows a peak YoY increase of 56.5% (in 2023) and a maximum YoY decrease of 152.21% (in 2023) over the last 5 years.
- Over the past 3 years, iBio's Liabilities from Discontinued Operations (Quarter) stood at $1.9 million in 2022, then fell by 0.56% to $1.9 million in 2023, then decreased by 0.15% to $1.9 million in 2024.
- Its Liabilities from Discontinued Operations was $1.9 million in Q1 2024, compared to $1.9 million in Q4 2023 and $1.9 million in Q3 2023.